New hope for AML patients who fail standard therapy: experimental combo trial launches
NCT ID NCT07505160
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests a new combination of drugs—lisafotoclax, decitabine, and homoharringtonine—in 35 adults with acute myeloid leukemia (AML) whose cancer did not respond to or could not tolerate the standard venetoclax/azacitidine regimen. The goal is to see if this new mix can shrink or eliminate the leukemia. Participants will receive the drugs in cycles and be followed for up to a year. The study is not yet recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- lisafotoclax (an experimental BCL-2 inhibitor) combined with decitabine and homoharringtonine
- What this could lead to
- If successful, this could offer a new treatment option for AML patients whose cancer no longer responds to standard venetoclax-based therapy.
- What could go wrong
- This is a small, early-phase trial with only 35 participants and no comparison group. The combination may cause serious side effects, and results may not apply to all AML patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Second Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310009, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new pill boost the power of an existing leukemia treatment?
- Can a new drug combo outperform standard care for a tough blood cancer?
- Can donor immune cells fight leukemia relapse after transplant?
- Can a liposomal chemo combo outsmart tough leukemias?
- Massive AML trial aims to find best chemo and transplant protection for younger patients
- New drug cocktail aims to stop leukemia return after transplant